Cambium Bio Advances Phase 3 with FDA Single-Trial Nod and A$2.4M Placement

FDA Greenlights Single-Trial Pathway for Elate Ocular®

Cambium Bio (ASX:CMB) has secured a critical regulatory win with the U.S. Food and Drug Administration confirming that a single adequate and well-controlled pivotal Phase 3 clinical trial, supplemented by confirmatory evidence, will suffice for a Biologics License Application (BLA) for its lead ophthalmology candidate, Elate Ocular®. This update, announced shortly after the quarter ended, aligns with the FDA's evolving approach to streamline approvals and potentially slashes both the cost and time to market for Cambium Bio.

The FDA’s agreement preserves the previously approved Phase 3 study design involving 400 evaluable patients and co-primary sign and symptom endpoints over a nine-week masked treatment period. This regulatory clarity significantly de-risks the pivotal trial stage and supports the company’s Fast Track Designation, enabling a rolling BLA submission anticipated by mid-2028. The confirmation follows Cambium Bio’s earlier FDA engagement and reflects the agency’s updated policy favoring single-trial approvals, as outlined in the New England Journal of Medicine earlier this year. Investors can view this as a substantial efficiency gain in the company’s clinical development pathway, reducing the regulatory burden compared to the historical two-trial requirement. This development was detailed in a recent FDA Greenlights Single Pivotal Trial announcement.

Strategic Placement Boosts Cash and Shareholder Alignment

Financially, Cambium Bio fortified its balance sheet with a A$2.4 million placement from its largest shareholder, Zheng Yang Biomedical Technology (ZYBT), which raised ZYBT’s stake from 28.1% to 39.6%. The placement price of A$0.55 per share represented a 20% premium to the closing price before the announcement, underscoring strong shareholder support. The capital injection, approved at an Extraordinary General Meeting in mid-March, arrived in the quarter and is earmarked for Phase 3 manufacturing, regulatory activities, and working capital.

ZYBT’s increasing influence, controlled by Non-Executive Director Dr Sebastian Tseng, signals deepening strategic alignment as Cambium Bio advances toward clinical milestones. The company’s cash position at quarter-end stood at A$2.246 million, with a net operating cash outflow of A$0.792 million primarily directed to research and development and manufacturing readiness. This follows earlier capital raises and partnerships that have collectively shored up funding for the pivotal Phase 3 program, as outlined in the company’s prior strategic deals and fresh funding update.

Manufacturing and CMC Advances Support Phase 3 Readiness

Cambium Bio continued to progress its Chemistry, Manufacturing, and Controls (CMC) program with a focus on both Phase 3 clinical supply and laying groundwork for commercial-scale production. The company extended drug substance stability data, reinforcing the proposed shelf-life and supply plans. Additionally, new pathogen inactivation steps were developed to meet FDA expectations, enhancing the viral safety profile of Elate Ocular®. Technology transfer efforts remain active with contract development and manufacturing organisations in Seattle and Taiwan, positioning the company to commence dosing in H2 2026 as planned.

These manufacturing milestones reduce operational risks ahead of the CAMOMILE-3 pivotal Phase 3 trial and underpin the company’s updated timeline, which targets topline data in Q4 2027 and potential BLA approval by late 2028. Cambium Bio’s lean operating model, relying heavily on CDMO and CRO partnerships, has helped contain personnel and administrative costs during this intensive development phase.

Funding Strategy Balances Non-Dilutive and Licensing Options

While the ZYBT placement provides a near-term capital buffer, Cambium Bio is actively pursuing a multi-pronged funding approach to support the Phase 3 program through to regulatory submission. This includes exploring R&D Tax Incentive (RDTI) pre-financing to accelerate access to cash refunds, advancing licensing discussions for Elate Ocular® in key markets such as the U.S., and evaluating further strategic equity investments. The company continues to generate recurring royalty income from its fibrinogen-depleted human platelet lysate cell culture supplement products, which also validate its underlying platform technology.

With the repayment of a US$152,000 tranche of its Georgia Research Alliance loan completed post quarter-end, Cambium Bio’s financial management appears disciplined and focused on maximizing runway. The company’s upcoming milestones include site activations and Phase 3 drug product manufacture in H2 2026, followed by patient enrolment and data readouts through 2027 and 2028.